MOXIFLOXACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H24FN3O4
Molecular Weight	401.4322
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COc1c2c(cc(c1N3C[C@]4([H])CCCN[C@]4([H])C3)F)c(=O)c(cn2C5CC5)C(=O)O

InChI

InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N

InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16337789 | https://www.ncbi.nlm.nih.gov/pubmed/20516287 | https://www.ncbi.nlm.nih.gov/pubmed/25801151 | https://www.ncbi.nlm.nih.gov/pubmed/11600361

Moxifloxacin is a synthetic antibacterial agent developed by Bayer AG (initially called BAY 12-8039) for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. Moxifloxacin is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avalon for oral treatment. In most countries, the drug is also available in the parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV subunit A 7 Target ID: CHEMBL4088 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16337789	Inhibitor 7728		800.0 nM [IC50]
DNA gyrase subunit A 6 Target ID: CHEMBL4165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20516287	Inhibitor 7728		9200.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Community acquired pneumonia 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf	Curative	Approved 8043	AVELOX Approved Use INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 9.4469757E11
Plague 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf	Curative	Approved 8043	AVELOX Approved Use INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 9.4469757E11
Acute bacterial sinusitis 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf	Curative	Approved 8043	AVELOX Approved Use INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 9.4469757E11

C_max

Value	Dose	Analyte	Population
3.1 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.9 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.5 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
443.07 ng/ml Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01296191	1 drop 4 times / day multiple, ocular dose: 1 drop route of administration: ocular experiment type: multiple co-administered:	MOXIFLOXACIN aqueous humor	Homo sapiens population: unhealthy age: sex: food status:

AUC

Value	Dose	Analyte	Population
36.1 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
38 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
39.3 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
48 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
13.55 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
14.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
60% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
60% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:		MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 1 times / day multiple, oral Higher than recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11352436 Page: p.5	healthy, 30±7 n = 7 Health Status: healthy Age Group: 30±7 Sex: M Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/11352436 Page: p.5	Sources: https://pubmed.ncbi.nlm.nih.gov/11352436 Page: p.5
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9687407 Page: p.2062	healthy, 33.6 n = 8 Health Status: healthy Age Group: 33.6 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/9687407 Page: p.2062	Sources: https://pubmed.ncbi.nlm.nih.gov/9687407 Page: p.2062
400 mg 1 times / day multiple, intravenous Recommended Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (>0.3) Diarrhea (>0.3) Dizziness (>0.3) Vomiting (>0.3) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23343427 Page: p.7	unhealthy, 57.8 n = 5 Health Status: unhealthy Condition: Chronic bronchitis Age Group: 57.8 Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/23343427 Page: p.7	Sources: https://pubmed.ncbi.nlm.nih.gov/23343427 Page: p.7
400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	Disc. AE: Erythema, QT interval prolonged... AEs leading to discontinuation/dose reduction: Erythema (0.37%) QT interval prolonged (1%) Angioedema (serious, 0.37%) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	Disc. AE: Tendinitis, Tendon rupture... AEs leading to discontinuation/dose reduction: Tendinitis Tendon rupture Peripheral neuropathy Central nervous system disorder NOS Myasthenia gravis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Rash	Disc. AE	400 mg 1 times / day multiple, intravenous Recommended Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Diarrhea	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Dizziness	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Nausea	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Vomiting	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Erythema	0.37% Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
QT interval prolonged	1% Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
Angioedema	serious, 0.37% Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
Central nervous system disorder NOS	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Myasthenia gravis	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Peripheral neuropathy	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Tendinitis	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Tendon rupture	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63611	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63611
MolPort	MolPort-006-167-494	https://www.molport.com/shop/molecule-link/MolPort-006-167-494
ZINC	ZINC000003826253	http://zinc15.docking.org/substances/ZINC000003826253
eMolecules	6843461	https://www.emolecules.com/cgi-bin/more?vid=6843461

PubMed

Title	Date	PubMed
Activity of moxifloxacin against mycobacteria.	1999 Sep	10511409
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.	2000 Dec	11083639
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.	2000 Jan	10718103
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.	2000 Oct	10991858
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.	2000 Sep	10952625
Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strains.	2001	11688532
Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.	2001	11352443
Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.	2001	11352442
Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.	2001	11352441
Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.	2001	11352440
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.	2001 Apr	11404068
Treatment of Staphylococcus aureus endocarditis using moxifloxacin.	2001 Aug	11554565
In vitro activity of fosfomycin in combination with various antistaphylococcal substances.	2001 Aug	11481290
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.	2001 Feb	11228817
[One year moxifloxacin. Still effective in the respiratory tract].	2001 Feb 15	11268757
Acute community-acquired pneumonia: current diagnosis and treatment.	2001 Jan	11227252
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.	2001 Jan	11120969
Drug Points: tachycardia associated with moxifloxacin.	2001 Jan 6	11141146
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.	2001 Jul	11561805
Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain.	2001 Jul	11418530
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.	2001 Mar	11222559
Clinical perspectives on new antimicrobials: focus on fluoroquinolones.	2001 Mar 15	11249831
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.	2001 Mar 15	11249827
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.	2001 Mar 15	11249826
Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.	2001 Mar 15	11249825
Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118.	2001 Mar 15	11249824
Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.	2001 Mar-Apr	11393351
Chronic obstructive pulmonary disease.	2001 Mar-Apr	11393348
In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.	2001 Mar-Apr	11173811
Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.	2001 Mar-Apr	11173809
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.	2001 May	11337224
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.	2001 Sep-Oct	11561138

Patents

Sample Use Guides

In Vivo Use Guide

The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection (5--21 days).

Route of Administration: Oral

In Vitro Use Guide

Phagocytosed bacteria were divided into four aliquots with different concentrations of the drug (0, 0.1, 1 and 10 MIC). At baseline and after 1, 2 and 4 h incubation, the number of viable bacteria was determined by a subculture technique. Moxifloxacin was active against all tested staphylococci with MICs of 0.063–2 mg/L.

Name

Type

Language

MOXIFLOXACIN

Official Name

English

MOXIFLOXACIN [INN]

Common Name

English

AVELOX IV

Brand Name

English

1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-((4AS,7AS)-OCTAHYDRO-6H-PYRROLO(3,4-B)PYRIDIN-6-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID

Common Name

English

MOXIFLOXACIN [VANDF]

Common Name

English

MOXIFLOXACIN [WHO-DD]

Common Name

English

ZIMOXIN

Brand Name

English

MOXIFLOXACIN [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

S01AX22